Stockreport

Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025 [Yahoo! Finance]

IPSEN SA S/ADR  (IPSEY) 
NASDAQ:AMEX Investor Relations: ipsen.com/investors
PDF Thu, February 13, 2025 at 6:57 AM GMT+1 8 min read In This Article IPSEF IPSEY Ipsen Pharma FY 2024 total sales growth of 9.9% at CER , or 8.7% as reported, [Read more]